Article de revue
Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa
Tuberculosis remains the leading cause of death in South Africa. A number of potential new TB vaccine candidates have been identified and are currently in clinical trials. One such candidate is MVA85A. This study aimed to estimate the cost-effectiveness of adding the MVA85A vaccine as a booster to the BCG vaccine in children from the perspective of the South African government.
Auteurs
Langues
- Anglais
Journal
Cost Eff Resour Alloc.
Volume
20
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Pays
- Afrique
- Afrique du Sud
